Validation of a targeted next-generation sequencing panel for tumor mutation burden analysis: results from the Onconetwork Immuno-Oncology Consortium
Tumor mutation burden (TMB) is evaluated as a biomarker of response to immunotherapy. We present the efforts of the Onconetwork Immuno-Oncology Consortium to validate a commercial targeted sequencing test for TMB calculation. A three-phase study was designed to validate the Oncomine Tumor Mutational...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
6 May 2021
|
| In: |
The journal of molecular diagnostics
Year: 2021, Jahrgang: 23, Heft: 7, Pages: 882-893 |
| ISSN: | 1943-7811 |
| DOI: | 10.1016/j.jmoldx.2021.04.008 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.jmoldx.2021.04.008 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1525157821001173 
|
| Verfasserangaben: | Francesca Fenizia, Ilaria Alborelli, Jose Luis Costa, Claudia Vollbrecht, Beatriz Bellosillo, Winand Dinjens, Volker Endris, Carina Heydt, Katharina Leonards, Sabine Merkelback-Bruse, Nicole Pfarr, Ronald van Marion, Christopher Allen, Ruchi Chaudhary, Rajesh Gottimukkala, Fiona Hyland, Elaine Wong-Ho, Philip Jermann, Jose Carlos Machado, Michael Hummel, Albrecht Stenzinger, and Nicola Normanno |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1767399502 | ||
| 003 | DE-627 | ||
| 005 | 20240414193302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210819s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jmoldx.2021.04.008 |2 doi | |
| 035 | |a (DE-627)1767399502 | ||
| 035 | |a (DE-599)KXP1767399502 | ||
| 035 | |a (OCoLC)1341420911 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Fenizia, Francesca |e VerfasserIn |0 (DE-588)1239313624 |0 (DE-627)1767400071 |4 aut | |
| 245 | 1 | 0 | |a Validation of a targeted next-generation sequencing panel for tumor mutation burden analysis |b results from the Onconetwork Immuno-Oncology Consortium |c Francesca Fenizia, Ilaria Alborelli, Jose Luis Costa, Claudia Vollbrecht, Beatriz Bellosillo, Winand Dinjens, Volker Endris, Carina Heydt, Katharina Leonards, Sabine Merkelback-Bruse, Nicole Pfarr, Ronald van Marion, Christopher Allen, Ruchi Chaudhary, Rajesh Gottimukkala, Fiona Hyland, Elaine Wong-Ho, Philip Jermann, Jose Carlos Machado, Michael Hummel, Albrecht Stenzinger, and Nicola Normanno |
| 264 | 1 | |c 6 May 2021 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 19.08.2021 | ||
| 520 | |a Tumor mutation burden (TMB) is evaluated as a biomarker of response to immunotherapy. We present the efforts of the Onconetwork Immuno-Oncology Consortium to validate a commercial targeted sequencing test for TMB calculation. A three-phase study was designed to validate the Oncomine Tumor Mutational Load (OTML) assay at nine European laboratories. Phase 1 evaluated reproducibility and accuracy on seven control samples. In phase 2, six formalin-fixed, paraffin-embedded samples tested with FoundationOne were reanalyzed with the OTML panel to evaluate concordance and reproducibility. Phase 3 involved analysis of 90 colorectal cancer samples with known microsatellite instability (MSI) status to evaluate TMB and MSI association. High reproducibility of TMB was demonstrated among the sites in the first and second phases. Strong correlation was also detected between mean and expected TMB in phase 1 (r2 = 0.998) and phase 2 (r2 = 0.96). Detection of actionable mutations was also confirmed. In colorectal cancer samples, the expected pattern of MSI-high/high-TMB and microsatellite stability/low-TMB was present, and gene signatures produced by the panel suggested the presence of a POLE mutation in two samples. The OTML panel demonstrated robustness and reproducibility for TMB evaluation. Results also suggest the possibility of using the panel for mutational signatures and variant detection. Collaborative efforts between academia and companies are crucial to accelerate the translation of new biomarkers into clinical research. | ||
| 700 | 1 | |a Alborelli, Ilaria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Costa, Jose Luis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vollbrecht, Claudia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bellosillo, Beatriz |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dinjens, Winand |e VerfasserIn |4 aut | |
| 700 | 1 | |a Endris, Volker |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heydt, Carina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Leonards, Katharina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Merkelback-Bruse, Sabine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pfarr, Nicole |e VerfasserIn |4 aut | |
| 700 | 1 | |a van Marion, Ronald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Allen, Christopher |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chaudhary, Ruchi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gottimukkala, Rajesh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hyland, Fiona |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wong-Ho, Elaine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Jermann, Philip |e VerfasserIn |4 aut | |
| 700 | 1 | |a Machado, Jose Carlos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hummel, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stenzinger, Albrecht |e VerfasserIn |0 (DE-588)139606106 |0 (DE-627)703395238 |0 (DE-576)312432755 |4 aut | |
| 700 | 1 | |a Normanno, Nicola |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The journal of molecular diagnostics |d Amsterdam [u.a.] : Elsevier, 1999 |g 23(2021), 7 vom: Juli, Seite 882-893 |h Online-Ressource |w (DE-627)324916922 |w (DE-600)2032654-3 |w (DE-576)309203805 |x 1943-7811 |7 nnas |a Validation of a targeted next-generation sequencing panel for tumor mutation burden analysis results from the Onconetwork Immuno-Oncology Consortium |
| 773 | 1 | 8 | |g volume:23 |g year:2021 |g number:7 |g month:07 |g pages:882-893 |g extent:12 |a Validation of a targeted next-generation sequencing panel for tumor mutation burden analysis results from the Onconetwork Immuno-Oncology Consortium |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jmoldx.2021.04.008 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1525157821001173 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210819 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 139606106 |a Stenzinger, Albrecht |m 139606106:Stenzinger, Albrecht |d 910000 |d 912000 |e 910000PS139606106 |e 912000PS139606106 |k 0/910000/ |k 1/910000/912000/ |p 21 | ||
| 999 | |a KXP-PPN1767399502 |e 3969941512 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Fenizia, Francesca","family":"Fenizia","role":"aut","given":"Francesca"},{"role":"aut","given":"Ilaria","display":"Alborelli, Ilaria","family":"Alborelli"},{"display":"Costa, Jose Luis","family":"Costa","role":"aut","given":"Jose Luis"},{"display":"Vollbrecht, Claudia","family":"Vollbrecht","role":"aut","given":"Claudia"},{"given":"Beatriz","role":"aut","family":"Bellosillo","display":"Bellosillo, Beatriz"},{"given":"Winand","role":"aut","family":"Dinjens","display":"Dinjens, Winand"},{"role":"aut","given":"Volker","display":"Endris, Volker","family":"Endris"},{"display":"Heydt, Carina","family":"Heydt","role":"aut","given":"Carina"},{"role":"aut","given":"Katharina","display":"Leonards, Katharina","family":"Leonards"},{"display":"Merkelback-Bruse, Sabine","family":"Merkelback-Bruse","role":"aut","given":"Sabine"},{"family":"Pfarr","display":"Pfarr, Nicole","given":"Nicole","role":"aut"},{"display":"van Marion, Ronald","family":"van Marion","role":"aut","given":"Ronald"},{"family":"Allen","display":"Allen, Christopher","given":"Christopher","role":"aut"},{"display":"Chaudhary, Ruchi","family":"Chaudhary","role":"aut","given":"Ruchi"},{"family":"Gottimukkala","display":"Gottimukkala, Rajesh","given":"Rajesh","role":"aut"},{"role":"aut","given":"Fiona","display":"Hyland, Fiona","family":"Hyland"},{"given":"Elaine","role":"aut","family":"Wong-Ho","display":"Wong-Ho, Elaine"},{"family":"Jermann","display":"Jermann, Philip","given":"Philip","role":"aut"},{"role":"aut","given":"Jose Carlos","display":"Machado, Jose Carlos","family":"Machado"},{"given":"Michael","role":"aut","family":"Hummel","display":"Hummel, Michael"},{"display":"Stenzinger, Albrecht","family":"Stenzinger","role":"aut","given":"Albrecht"},{"given":"Nicola","role":"aut","family":"Normanno","display":"Normanno, Nicola"}],"recId":"1767399502","relHost":[{"pubHistory":["1.1999,1(Nov.) -"],"recId":"324916922","note":["Gesehen am 17.01.20"],"title":[{"title_sort":"journal of molecular diagnostics","title":"The journal of molecular diagnostics"}],"language":["eng"],"disp":"Validation of a targeted next-generation sequencing panel for tumor mutation burden analysis results from the Onconetwork Immuno-Oncology ConsortiumThe journal of molecular diagnostics","titleAlt":[{"title":"JMD online"}],"part":{"extent":"12","year":"2021","pages":"882-893","text":"23(2021), 7 vom: Juli, Seite 882-893","issue":"7","volume":"23"},"type":{"bibl":"periodical","media":"Online-Ressource"},"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2032654-3"],"eki":["324916922"],"issn":["1943-7811"]},"corporate":[{"display":"American Society for Investigative Pathology","role":"isb"},{"display":"Association for Molecular Pathology","role":"isb"}],"name":{"displayForm":["the American Society for Investigative Pathology and the Association for Molecular Pathology"]},"origin":[{"dateIssuedKey":"1999","dateIssuedDisp":"1999-","publisher":"Elsevier ; Soc.","publisherPlace":"Amsterdam [u.a.] ; Bethesda, Md."}]}],"language":["eng"],"note":["Gesehen am 19.08.2021"],"title":[{"subtitle":"results from the Onconetwork Immuno-Oncology Consortium","title_sort":"Validation of a targeted next-generation sequencing panel for tumor mutation burden analysis","title":"Validation of a targeted next-generation sequencing panel for tumor mutation burden analysis"}],"origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"6 May 2021"}],"physDesc":[{"extent":"12 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Francesca Fenizia, Ilaria Alborelli, Jose Luis Costa, Claudia Vollbrecht, Beatriz Bellosillo, Winand Dinjens, Volker Endris, Carina Heydt, Katharina Leonards, Sabine Merkelback-Bruse, Nicole Pfarr, Ronald van Marion, Christopher Allen, Ruchi Chaudhary, Rajesh Gottimukkala, Fiona Hyland, Elaine Wong-Ho, Philip Jermann, Jose Carlos Machado, Michael Hummel, Albrecht Stenzinger, and Nicola Normanno"]},"id":{"doi":["10.1016/j.jmoldx.2021.04.008"],"eki":["1767399502"]}} | ||
| SRT | |a FENIZIAFRAVALIDATION6202 | ||